Information Provided By: 
Fly News Breaks for July 25, 2016
SHPG
Jul 25, 2016 | 08:16 EDT
SunTrust analyst John Boris says that Shire can benefit from economies of scale from its long duration rare disease drugs, giving it a "superior growth outlook." The analyst expects the company to raise its cost synergies target to $750M from $500M on its Q2 results call. He reiterates a $298 price target and Buy rating on the shares.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
